bayesynergy: flexible Bayesian modelling of synergistic interaction effects in in vitro drug combination experiments

Author:

Rønneberg Leiv1,Cremaschi Andrea2,Hanes Robert34,Enserink Jorrit M345,Zucknick Manuela1

Affiliation:

1. Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Norway

2. Singapore Institute for Clinical Sciences (SICS), A*STAR, Singapore

3. Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo 0379, Norway

4. Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

5. Department of Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, PO Box 1066 Blindern, Oslo 0316, Norway

Abstract

Abstract The effect of cancer therapies is often tested pre-clinically via in vitro experiments, where the post-treatment viability of the cancer cell population is measured through assays estimating the number of viable cells. In this way, large libraries of compounds can be tested, comparing the efficacy of each treatment. Drug interaction studies focus on the quantification of the additional effect encountered when two drugs are combined, as opposed to using the treatments separately. In the bayesynergy R package, we implement a probabilistic approach for the description of the drug combination experiment, where the observed dose response curve is modelled as a sum of the expected response under a zero-interaction model and an additional interaction effect (synergistic or antagonistic). Although the model formulation makes use of the Bliss independence assumption, we note that the posterior estimates of the dose–response surface can also be used to extract synergy scores based on other reference models, which we illustrate for the Highest Single Agent model. The interaction is modelled in a flexible manner, using a Gaussian process formulation. Since the proposed approach is based on a statistical model, it allows the natural inclusion of replicates, handles missing data and uneven concentration grids, and provides uncertainty quantification around the results. The model is implemented in the open-source Stan programming language providing a computationally efficient sampler, a fast approximation of the posterior through variational inference, and features parallel processing for working with large drug combination screens.

Funder

Research Council of Norway through its Centers of Excellence

South-Eastern Norway Regional Health Authority

Publisher

Oxford University Press (OUP)

Subject

Molecular Biology,Information Systems

Reference36 articles.

1. Uber Kombinationswirkungen;Loewe;Naunyn Schmiedebergs Arch Exp Pathol Pharmakol,1926

2. The toxicity of poisons applied jointly;Bliss;Ann Appl Biol,1939

3. The search for synergy: a critical review from a response surface perspective;Greco;Pharmacol Rev,1995

4. Analysis of drug combinations: current methodological landscape;Fouquier;Pharmacol Res Perspect,2015

5. Quantifying drug combination synergy along potency and efficacy axes;Meyer;Cell Syst,2019

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3